Sigachi Industries, manufacturer of pharmaceutical excipients and active ingredients, has received the Terms of Reference (ToR) from the State Environment Impact Assessment Authority (SEIAA), Andhra Pradesh. The approval marks a critical first step for the company’s proposed bulk drugs, drug intermediates, and specialty chemicals manufacturing unit in Orvakal, Kurnool district.
Project Development Timeline and Location
With the ToR in place, Sigachi is set to initiate the environmental clearance (EC) process on 15 July 2025, followed by project development starting on 01 August 2025. The facility will span 25.09 acres.
Enhancing API Production and Export Capability
The strategic investment will significantly expand Sigachi’s API manufacturing capacity. This expansion will enable the company to cater more effectively to regulated and semi-regulated markets across the globe. Once operational, the new facility will also function as a key export hub, supporting India’s growing role in the global pharmaceutical supply chain.
Reinforcing Global Competitiveness
As reported by projectstoday.com, Sigachi Industries is strengthening its commitment through this expansion. The company aims to scale up pharmaceutical manufacturing infrastructure. It also seeks to support India’s ambition to become a leading global supplier of bulk drugs and intermediates. The project also aligns with national priorities to boost self-reliance in pharmaceutical production. It aims to reduce import dependency in critical sectors.
